Opinion

Video

Introduction to CAR T-Cell Therapies in R/R ALL

Panelists discuss how the recent FDA approval of obecabtagene autoleucel (obe-cel) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) adds to the existing chimeric antigen receptor (CAR) T-cell therapies, with a focus on the differences in their mechanisms, structures, and FDA indications.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • We recently had a third CAR T-cell therapy, obe-cel, approved for R/R ALL. Could you introduce the 3 CAR T-cell therapies that are currently available, including their FDA indications, general mechanisms of action, and differences in structure?

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data